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Objective: Repetitive transcranial magnetic stimulation (rTMS) can enhance the excitement of the brain through
adjusting the biological activities of the cerebral cortex and has wide biological effects, making it one basic
mechanism of therapy for depression. In the treatment of unipolar depressive disorder, almost in every treatment
method, hypomanic and manic shifts can be observed. There is still a lack of data regarding manic and hypomanic
symptoms triggered by rTMS applications.
Method: We describe four cases with unipolar depression in which high-frequency rTMS over the left dorsolateral
prefrontal cortex applied as an add-on antidepressive strategy may have induced a hypomanic episode.
Results: In these cases, 25 Hz rTMS combined with antidepressants may have contributed to the occurrence of
hypomanic symptoms.
Conclusion: Using an intensive methodology of rTMS may induce hypomanic or manic symptoms.
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Repetitive transcranial magnetic stimulation (rTMS) can
increase the excitability of the brain through changing
the activity of the cerebral cortex. This has widespread
biological effects, which have made it a basic therapeutic
mechanism for depression [1]. In 2008, the US Food and
Drug Administration approved rTMS as an alternative
form of treatment for treatment-resistant depression [2].
Mania has been observed in depression treatments
based on pharmacotherapy, electroconvulsive therapy,
vagus nerve stimulation, sleep deprivation, and deep
brain stimulation used to treat obsessive-compulsive dis-
order (OCD) [3-6]. In the treatment of unipolar depres-
sive disorders, hypomania and mania have been
observed in almost every treatment method, while in the
treatment of bipolar disorder depressive episodes, the
frequency of hypomania and mania is even higher [7].
Xia et al. reviewed cases of hypomania and mania
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reproduction in any medium, provided the orperiod 1966 to 2006 [8]. Treatment-emergent hypo-
mania/mania rates were shown to be 0.84% in the active
rTMS group and 0.73% in the sham group. This diffe-
rence was not statistically significant. The same authors
showed that during rTMS treatment for unipolar de-
pression, the emergent hypomania/mania rate was
0.34%, while the rate in bipolar disorder depressive epi-
sodes, it was 3.1%.
Sakkas et al. looked at treatment-resistant unipolar de-
pression [9]. Manic symptoms were detected with high-
frequency 20 Hz rTMS applied over the left dorsolateral
prefrontal cortex (LDLPFC), at 1,600 pulses, twice daily
and citalopram. Ella et al. reported manic symptoms in a
patient with recurrent major depressive disorder treated
with 1 Hz rTMS applied over the right dorsolateral pre-
frontal cortex (RDLPFC) at 1,200 pulses/day and tranyl-
cypromine, haloperidol, and lorazepam [10]. George et al.
monitored hypomanic symptoms in a patient with major
depressive disorder following a 9-day application of 20-Hz
rTMS over the LDLPFC at 400 pulses twice daily [11]. In
light of this earlier literature, this article reports the results
of the treatment of four patients with unipolar depressiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ozten et al. Annals of General Psychiatry 2013, 12:12 Page 2 of 5
http://www.annals-general-psychiatry.com/content/12/1/12who were monitored for symptoms of hypomania/mania
following daily rTMS treatment at 25 Hz, 100% motor




The first case was that of a 21-year-old male patient ex-
periencing his second depressive episode. Three years
ago, during his first episode, he benefited from treatment
with fluoxetine 20 mg/day. The second episode had
begun 4 months earlier. His symptoms included sadness,
unhappiness, reluctance, lack of academic progress, so-
cial isolation, and difficulty in falling asleep. He had no
psychotic symptoms. His Hamilton Depression Rating
(HAM-D 17) score on admission was 27, despite treat-
ment with fluoxetine 40 mg/day for the previous 3
months. His grandfather had a history of psychotic dis-
orders. Biochemistry, complete blood count, TIT, TFT,
vitamin B12, and folic acid levels were normal, and no
pathology was detected in electroencephalogram (EEG)
and cranial magnetic resonance imaging (MRI). Consid-
ered treatment-resistant, escitalopram 10 mg/day and 25
Hz, 1,000 pulses, 100% MT, LDLPFC rTMS were started.
After the ninth session, the quantity and speed of his
speech had increased, his need for sleep had reduced,
and he showed increased mobility, elevated affect, and
increased psychomotor activity. His score on the Young
Mania Scale was 24. In response to these hypomanic
symptoms, the rTMS protocol was changed to 1 Hz, 250
pulses, RDLPFC. Eleven sessions followed using this
protocol. Escitalopram was stopped, and the treatment
continued with sodium valproate 1,000 mg/day. He was
discharged in euthymic condition. In the 12th month of
treatment, he was still euthymic, and treatment with so-
dium valproate was ongoing.
Second case
The second case was that of a 48-year-old female patient
experiencing her second depressive episode. Ten years
ago, she recovered from her first depressive episode
without medication and with psychotherapy. In the 5
months before treatment, she had complained of symp-
toms such as anxiety, depressed mood, decreased appe-
tite, weight loss, and anhedonia. The patient had been
taking sertraline 200 mg/day for the previous 2 months
but showed no improvement. She had no psychotic
symptoms. Her HAM-D 17 score was 24. Her bioche-
mical measures were within normal range, and no path-
ology was detected in EEG and cranial MRI. Considered
treatment-resistant, venlafaxine 150 mg/day and 25 Hz,
1,000 pulses, 100% MT, LDLPFC rTMS were started.
After 14 sessions, the patient manifested euphoria, sleep-
lessness, and increased energy and speech. Her score onthe Young Mania Scale was 28. In response to these
hypomanic symptoms, the rTMS treatment was changed
to 1 Hz, 250 pulses, RDLPFC, and six sessions were ap-
plied. Venlafaxine was stopped, and the treatment was
continued with sodium valproate 1,000 mg/day. She was
discharged in euthymic condition. By the ninth month
of treatment, she was still euthymic, and sodium valpro-
ate treatment was ongoing.
Third case
The third case concerned a 38-year-old female patient
diagnosed with unipolar depressive disorder. Although
she had been taking paroxetine 40 mg/day for the past 3
years, she had not taken any psychotropic medications
in the previous 2 years. She described a ten-month depres-
sive episode and had been taking fluoxetine 40 mg/day for
the previous 2 months with no improvement. Her symp-
toms included depression, anhedonia, anxiety, low self-
esteem, and decreased functioning. Her HAM-D 17 score
was 22. No OCD symptoms were observed. Her bioche-
mical measures were within normal range, and no path-
ology was detected in EEG and cranial MRI. Considered
to be suffering from treatment-resistant depression, her
fluoxetine dose was adjusted to 60 mg/day, and 25 Hz,
1,000 pulses, 100% MT, LDLPFC rTMS was started. No
psychotic symptoms were detected. After 12 sessions, she
manifested euphoria, sleeplessness, and increased energy
and speech, and her score on the Young Mania Scale was
20. In response to her hypomanic symptoms, rTMS was
changed to 1 Hz, 250 pulses, RDLPFC, and eight sessions
were applied. Fluoxetine was stopped, and treatment con-
tinued with sodium valproate 1,000 mg/day. She was
discharged in euthymic condition after 2 weeks. In the
fourth month of treatment, she was still euthymic, and
treatment with sodium valproate was ongoing.
Fourth case
This concerned a 23-year-old female patient experiencing
her second depressive episode. During her first episode 3
years earlier, she had attempted suicide. Consequently, she
was hospitalized, and drug therapy consisted of escita-
lopram 20 mg/day and trazadone 100 mg/day. During
follow-up, she was considered euthymic. Her treatment
had gradually stopped working 1 year earlier, and 3
months earlier, her depressive symptoms including dif-
ficulty in falling asleep, anhedonia, lack of drive, loss of
appetite, weight loss, low self-esteem, and loss of function-
ality had returned. She had no psychotic symptoms. Her
HAM-D 17 score was 26. Her biochemical measures were
within normal range, and no pathology was detected in
EEG. As the patient had previously benefited from treat-
ment with escitalopram and trazadone, this was resumed
but with no improvement. Drug therapy was changed to
escitalopram 20 mg/day and mirtazapine 30 mg/day, and
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to the treatment program. After 12 sessions, she manifested
euphoria, sleeplessness, and increased energy and speech.
Her Young Mania score was 22. In response to these hypo-
manic symptoms, 1 Hz, 250 pulses, RDLPFC rTMS was
applied for eight sessions. Escitalopram and mirtazapine
were stopped, and the treatment was continued with so-
dium valproate 1,000 mg/day. She was discharged in
euthymic condition. In the eighth month of treatment, she
was still euthymic, and her sodium valproate treatment was
ongoing. Table 1 summarizes these four cases.Discussion
Bipolar depression is associated with mania-hypomania,
and natural switch rates are considered to be approxi-
mately 4.6% to 6.7% [8]. The review by Xia et al. of
controlled clinical studies showed that the risk of
hypomania-mania shift in bipolar depression was nine
times higher than in unipolar depression [8]. They argued
that this might be because patients with bipolar depres-
sion had been mistakenly evaluated as unipolar. In order
to avoid such mistakes, we investigated both the manic
and hypomanic histories of patients and their families in
detail, and no such history was found.
The same study found that emergent hypomania-
mania rates in rTMS treatments were 0.84% in the
rTMS group and 0.73% in the sham group and that fol-
lowing the application of rTMS treatment for unipolar
depression, the hypomania-mania shift rate was 0.34%,
while in bipolar disorder depressive phase, the rate was
3.1%. Mood switching was considered to be related to
the nature of the disease and aggressive doses of rTMS
[8]. Similarly, in the case studies reported by Sakkas
et al. and Hausmann et al., hypomania-mania symptoms
were observed during 20 Hz rTMS applications [9,12].
In the present report, cases of 419 patients treated be-

































None None 25 Hz, 100
LDLPFC, 1,
session daIn the Hausmann et al. study, manic symptoms oc-
curred during 20 Hz, 2,000 pulses rTMS treatment of a
patient with bipolar depression [12]. When the protocol
was changed to 1 Hz, 1,200 pulses, RDLPFC, and antide-
pressants were replaced by clozapine, manic symptoms
disappeared. The rTMS protocol in our four cases was
25 Hz, LDLPFC, 1,000 pulses/day, and 100% MT. Hypo-
manic symptoms were observed during the initial treat-
ment period in all four of our cases. In each case,
antidepressants were replaced by valproic acid, and the
protocol was changed to 1 Hz, 250 pulses RDLPFC. In
all cases, hypomanic symptoms disappeared following
the protocol changes. This could be related to either the
impact of the change in medication or changes in the
rTMS application. However, it should be noted that Ella
et al. observed manic symptoms in a patient with recur-
rent major depressive disorder taking tranylcypromine,
haloperidol, and lorazepam and treated with 1 Hz, 1,200
pulses, RDLPFC rTMS [10]. This result is in contrast to
our findings and demonstrates that there is still a lack of
data regarding manic and hypomanic symptoms trig-
gered by rTMS applications.
It is known that any remedial effects of treatment can
potentially arise from two sources: one related to the
specific properties of the treatment and the other associ-
ated with the patient's expectations for the treatment
(placebo effect). The magnitude of the placebo effect
varies according to its supposed effectiveness and emo-
tional impact on the treated subject [13]. Many studies
reported response rates for patients who received pla-
cebo treatment. Klein et al. reported a control group
response rate as high as 25% [14]. Patients receiving pla-
cebo rTMS may receive a small dose of magnetic energy
that may alter their depression.
There are many variations in the way rTMS can be
given as a clinical treatment, involving choices over
treatment site, stimulation parameters, and treatment







9 Escitalopram stopped. Valproic acid





14 Venlafaxine stopped. Valproic acid added.





12 Fluoxetine stopped. Valproic acid added.





12 Escitalopram and mirtazapine stopped.
Valproic acid added. Eight sessions of 1 Hz,
250 pulses, RDLPFC rTMS applied
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parameters, except in deliberate attempts at replication.
High-frequency rTMS to the left prefrontal cortex has
been used in most trials, a choice influenced by positive
early results from this approach. Imaging studies have
shown evidence of reduced blood flow in the left pre-
frontal cortex in patients with depression [15]. Some in-
vestigators have tried low-frequency rTMS to the right
prefrontal cortex. Motor cortex studies suggest that
high- and low-frequency rTMS have opposite effects on
the excitability of neurons in the brain cortex [16]. There
is considerable evidence from neuropsychological, lesion,
and imaging studies that the left and right hemispheres
have contrasting roles in mood regulation [17]. There-
fore, it might be expected that low-frequency rTMS to
the right prefrontal cortex may be as likely to have anti-
depressant effects as high-frequency rTMS to the left
prefrontal cortex. However, there is no strong evidence
for either side in the peer-reviewed literature. Stimulus
frequency of rTMS was within the range of 5 to 25 Hz
in several studies as changes in cortical excitability have
been demonstrated with this range of frequency [16].
Results suggest that higher stimulus frequencies may
have greater antidepressant potency. The majority of
rTMS trials have reported stimulus intensity relative to
the subject's resting motor threshold, that is, the lowest
stimulus intensity necessary to produce a motor re-
sponse in a relaxed contralateral muscle when TMS is
given over the primary motor cortex. Researchers have
reported that stimulus intensity is an important factor in
inducing lasting changes in cortical excitability that may
be responsible for antidepressant effects. In depressed
subjects, studies comparing different intensities of
stimulation (100% and 90% of motor threshold) showed
that higher stimulation intensity was significantly associ-
ated with greater improvement [18]. However, an over-
view of studies in the literature does not support an
association between higher intensities (110% or 120% of
motor threshold) and greater response rates. rTMS trials
have moved in the direction of administering longer-
duration protocols with greater doses of magnetic pulses
[19-21]. These clinical studies suggest that treating de-
pressed patients with higher doses improves response
and remission rates with rTMS.
The main limitation of our report is that, in each of the
four cases, the rTMS was initiated together with initiation
or increase of high-dose antidepressant medication.
Therefore, the ‘switch’ may also be due to the antidepres-
sant medication and cannot be necessarily contributed to
rTMS. However, further research is needed on this topic.
Conclusion
We conclude that using an intensive methodology of
rTMS may induce hypomanic or manic symptoms.Consent
Written informed consent was obtained from the patients
for publication of this Case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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